Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: A multicenter study of the Splenic B-Cell Lymphoma Group

Blood

Volumn 116, Issue 9, 2010, Pages 1479-1488

  Salido, Marta ^a,b   Baró, Cristina ^a,b   Oscier, David ^c   Stamatopoulos, Kostas ^d   Dierlamm, Judith ^e   Matutes, Estela ^f   Traverse Glehen, Alexandra ^g,h   Berger, Francoise ^g,h   Felman, Pascale ^g,h   Thieblemont, Catherine ⁱ   Gesk, Stefan ^j   Athanasiadou, Anastasia ^d   Davis, Zadie ^c   Gardiner, Anne ^c   Milla, Fuensanta ^k   Ferrer, Ana ^a   Mollejo, Manuela ^l   Calasanz, Maria José ^m   Florensa, Lourdes ^a   Espinet, Blanca ^a   Luño, Elisa ⁿ   Wlodarska, Iwona ^o   Verhoef, Gregor ^p   García Granero, Marta ^m   Salar, Antonio ^a   Papadaki, Theodora ^q   Serrano, Sergio ^a   Piris, Miguel A ^r   Solé, Francesc ^a   more..

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^d G PAPANICOLAOU HOSPITAL   (Greece)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g CENTRE HOSPITALIER LYON SUD   (France)

^h UNIVERSITÉ LYON 1   (France)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^k HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^l HOSPITAL VIRGEN DE LA SALUD   (Spain)

^m UNIVERSITY OF NAVARRA   (Spain)

ⁿ HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^o UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^p UNIVERSITY OF LEUVEN   (Belgium)

^q EVANGELISMOS HOSPITAL   (Greece)

^r Centro Nacional de Investigaciones Oncológicas   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN VARIABLE REGION;

ADULT; AGED; CHROMOSOME ABERRATION; CLINICAL TRIAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; KARYOTYPING; MALE; MARGINAL ZONE LYMPHOMA; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDY; SPLEEN TUMOR; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; DNA, NEOPLASM; FEMALE; GENES, P53; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDIES; SPLENIC NEOPLASMS; SURVIVAL RATE;

EID: 77956592193     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-267476     Document Type: Article

References (53)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
2. Mollejo M, Menarguez J, Lloret E, et al. Splenic marginal zone lymphoma: a distinctive type of low-grade B-cell lymphoma: a clinicopathological study of 13 cases. Am J Surg Pathol. 1995;19(10):1146-1157.
3. Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22(3):487-495. (Pubitemid 351386718)
4. Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Catovsky D. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood. 1994;83(6):1558-1562.
5. Thieblemont C, Nasser V, Felman P, et al. Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood. 2004;103(7):2727-2737. (Pubitemid 38393031)
6. Oscier DG, Matutes E, Gardiner A, et al. Cytogenetic studies in splenic lymphoma with villous lymphocytes. Br J Haematol. 1993;85(3):487-491.
7. Dierlamm J, Pittaluga S, Wlodarska I, et al. Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood. 1996;87(1):299-307. (Pubitemid 26011844)
8. Dierlamm J, Michaux L, Wlodarska I, et al. Trisomy 3 in marginal zone B-cell lymphoma: a study based on cytogenetic analysis and fluorescence in situ hybridization. Br J Haematol. 1996;93(1):242-249.
9. Troussard X, Mauvieux L, Radford-Weiss I, et al. Genetic analysis of splenic lymphoma with villous lymphocytes: a Groupe Francais d'Hematologie Cellulaire (GFHC) study. Br J Haematol. 1998;101(4):712-721.
10. Sole F, Salido M, Espinet B, et al. Splenic marginal zone B-cell lymphomas: two cytogenetic subtypes, one with gain of 3q and the other with loss of 7q. Haematologica. 2001;86(1):71-77. (Pubitemid 32147054)
11. Sole F, Espinet B, Salido M, et al. Translocation t(6;14)(p12;q32): a novel cytogenetic abnormality in splenic lymphoma with villous lymphocytes. Br J Haematol. 2000;110(1):241-243.
12. Callet-Bauchu E, Baseggio L, Felman P, et al. Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases. Leukemia. 2005;19(10):1818-1823.
13. Gruszka-Westwood AM, Hamoudi RA, Matutes E, Tuset E, Catovsky D. p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood. 2001;97(11):3552-3558.
14. Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood. 2005;106(5):1831-1838. (Pubitemid 41208601)
15. Algara P, Mateo MS, Sanchez-Beato M, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood. 2002;99(4):1299-1304.
16. International Standing Committee on Human Cytogenetic Nomenclature, Shaffer LG, Tommerup N. ISCN 2005: An International System for Human Cytogenetic Nomenclature (2005). Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 2005.
17. Baro C, Salido M, Espinet B, et al. New chromosomal alterations in a series of 23 splenic marginal zone lymphoma patients revealed by Spectral Karyotyping (SKY). Leuk Res. 2008;32(5):727-736.
18. Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006;107(12):4643-4649.
19. Gruszka-Westwood AM, Hamoudi R, Osborne L, Matutes E, Catovsky D. Deletion mapping on the long arm of chromosome 7 in splenic lymphoma with villous lymphocytes. Genes Chromosomes Cancer. 2003;36(1):57-69. (Pubitemid 36077382)
20. Andersen CL, Gruszka-Westwood A, Atkinson S, et al. Recurrent genomic imbalances in B-cell splenic marginal-zone lymphoma revealed by comparative genomic hybridization. Cancer Genet Cytogenet. 2005;156(2):122-128.
21. Brynes RK, Almaguer PD, Leathery KE, et al. Numerical cytogenetic abnormalities of chromosomes 3, 7, and 12 in marginal zone B-cell lymphomas. Mod Pathol. 1996;9(10):995-1000.
22. Gazzo S, Baseggio L, Coignet L, et al. Cytogenetic and molecular delineation of a region of chromosome 3q commonly gained in marginal zone B-cell lymphoma. Haematologica. 2003;88(1):31-38.
23. Hernandez JM, Garcia JL, Gutierrez NC, et al. Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics. Am J Pathol. 2001;158(5):1843-1850.
24. Mateo M, Mollejo M, Villuendas R, et al. 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol. 1999;154(5):1583-1589. (Pubitemid 29226452)
25. Andersen CL, Gruszka-Westwood A, Ostergaard M, et al. A narrow deletion of 7q is common to HCL, and SMZL, but not CLL. Eur J Haematol. 2004;72(6):390-402.
26. Vega F, Cho-Vega JH, Lennon PA, et al. Splenic marginal zone lymphomas are characterized by loss of interstitial regions of chromosome 7q, 7q31.32 and 7q36.2 that include the protection of telomere 1 (POT1) and sonic hedgehog (SHH) genes. Br J Haematol. 2008;142:216-226.
27. Remstein ED, Law M, Mollejo M, Piris MA, Kurtin PJ, Dogan A. The prevalence of IG translocations and 7q32 deletions in splenic marginal zone lymphoma. Leukemia. 2008;22(6):1268-1272. (Pubitemid 351833799)
28. Sonoki T, Harder L, Horsman DE, et al. Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood. 2001;98(9):2837-2844.
29. Baro C, Salido M, Domingo A, et al. Translocation t(9;14)(p13;q32) in cases of splenic marginal zone lymphoma. Haematologica. 2006;91(9):1289-1291. (Pubitemid 44408451)
30. Martin-Subero JI, Ibbotson R, Klapper W, et al. A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation. Leukemia. 2007;21(7):1532-1544.
31. Michaux L, Dierlamm J, Wlodarska I, et al. t(14;19)/BCL3 rearrangements in lymphoproliferative disorders: a review of 23 cases. Cancer Genet Cytogenet. 1997;94:36-43.
32. Huh YO, Abruzzo LV, Rassidakis GZ, et al. The t(14;19)(q32;q13)-positive small B-cell leukaemia: a clinicopathologic and cytogenetic study of seven cases. Br J Haematol. 2007;136(2):220-228.
33. Pospisilova H, Baens M, Michaux L, et al. Interstitial del(14)(q) involving IGH: a novel recurrent aberration in B-NHL. Leukemia. 2007;21(9):2079-2083.
34. Giannouli S, Paterakis G, Ziakas PD, Anagnostou D, Voulgarelis M. Splenic marginal zone lymphomas with peripheral CD5 expression. Haematologica. 2004;89(1):113-114. (Pubitemid 38165867)
35. Baseggio L, Traverse-Glehen A, Petinataud F, et al. CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathologic, cytogenetic and molecular study of 24 cases. Haematologica. 2010;95(4):604-612.
36. Gimeno E, Salido M, Sole F, et al. CD5 negative and CD5 positive splenic marginal B-cell lymphomas have differential cytogenetic patterns. Leuk Res. 2005;29(8):981-982.
37. Boonstra R, Bosga-Bouwer A, van Imhoff GW, et al. Splenic marginal zone lymphomas presenting with splenomegaly and typical immunophenotype are characterized by allelic loss in 7q31-32. Mod Pathol. 2003;16(12):1210-1217.
38. Fernàndez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70(4):1408-1418.
39. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94(11):1555-1562.
40. Traverse-Glehen A, Davi F, Ben Simon E, et al. Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection. Haematologica. 2005;90(4):470-478.
41. Stamatopoulos K, Belessi C, Papadaki T, et al. Immunoglobulin heavy- and light-chain repertoire in splenic marginal zone lymphoma. Mol Med. 2004;10(7):89-95.
42. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-1847.
43. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-1854. (Pubitemid 29430400)
44. Ghia P, Stamatopoulos K, Belessi C, et al. European Research Initiative on CLL: ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia. 2007;21(1):1-3.
45. Arcaini L, Zibellini S, Passamonti F, et al. Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires. Blood Cells Mol Dis. 2009;42(3):286-291.
46. Kalpadakis C, Pangalis GA, Dimitriadou E, et al. Mutation analysis of IgVH genes in splenic marginal zone lymphomas: correlation with clinical characteristics and outcome. Anticancer Res. 2009;29(5):1811-1816.
47. Novara F, Arcaini L, Merli M, et al. High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma. Hum Pathol. 2009;40(11):1628-1637.
48. Athanasiadou A, Stamatopoulos K, Gaitatzi M, Stavroyianni N, Fassas A, Anagnostopoulos A. Recurrent cytogenetic findings in subsets of patients with chronic lymphocytic leukemia expressing IgG-switched stereotyped immunoglobulins. Haematologica. 2008;93(3):473-474.
49. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 2007;109(1):259-270.
50. Chacon JI, Mollejo M, Munoz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood. 2002;100(5):1648-1654.
51. Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hematologie Cellulaire (GFHC). Br J Haematol. 1996;93(3):731-736.
52. Thieblemont C. Non-MALT marginal zone lymphomas. Ann Oncol. 2008;19(suppl 4):iv70-3.
53. Parry-Jones N, Matutes E, Gruszka-Westwood AM, et al. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol. 2003;120(5):759-764. (Pubitemid 36315095)